Evidence map›Paper›PMID 25411976›Full record

Trial reportPloS one2014

Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.

Hasriza Hashim, Shahrul Azmin, Hamizah Razlan, Nafisah Wan Yahya, Hui Jan Tan, M Rizal Abdul Manaf, Norlinah Mohamed Ibrahim

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02112812 (A Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's Disease), which is not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 3 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02112812 nacompletednot on this map

A Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's Disease

TypeinterventionalSponsorNational University of MalaysiaRan2012 to 2013Enrolled82ConditionsResponse to Levodopa, Motor Outcomes, Quality of Life OutcomesArmsEradication therapy for H.pylori infection, Eradication of Helcobacter Pylori, Eradication therapy for Helicobacter pylori
3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Mass Spectrometry Applications to Study Human Microbiome.Advances in experimental medicine and biology · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hasriza HashimNeurology Unit, Department of Medicine, UKM Medical Center, Kuala Lumpur, Malaysia.
Shahrul AzminNeurology Unit, Department of Medicine, UKM Medical Center, Kuala Lumpur, Malaysia.
Hamizah RazlanNeurology Unit, Department of Medicine, UKM Medical Center, Kuala Lumpur, Malaysia.
Nafisah Wan YahyaNeurology Unit, Department of Medicine, UKM Medical Center, Kuala Lumpur, Malaysia.
Hui Jan TanNeurology Unit, Department of Medicine, UKM Medical Center, Kuala Lumpur, Malaysia.
M Rizal Abdul ManafDepartment of Community Health, UKM Medical Center, Kuala Lumpur, Malaysia.
Norlinah Mohamed IbrahimNeurology Unit, Department of Medicine, UKM Medical Center, Kuala Lumpur, Malaysia.
University Kebangsaan Malaysia Medical Centre · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies have demonstrated a higher prevalence of Helicobacter pylori (H. pylori) infection in patients with Parkinson's disease (PD) compared to controls. H. pylori infection affects levodopa absorption and its eradication significantly improves clinical response to levodopa. Here, we studied the prevalence of H. pylori infection and its eradication effects among our PD patients.

methodsA prospective study involving idiopathic PD patients on levodopa therapy. 13C-urea breath test (UBT) was used to detect H. pylori. UBT-positive patients were given standard eradication therapy and followed up at 6 and 12 weeks in an open label single arm design. Repeat UBT was performed at 12 weeks. The UPDRS, PD NMQ, PD NMSS and PDQ-39 were administered at baseline and post-eradication (6 and 12 weeks). Levodopa 'onset' time and ON-duration were recorded.

resultsOf 82 patients recruited, 27 (32.9%) had positive UBT. H. pylori-positive patients had significantly poorer total UPDRS (p = 0.005) and PDQ39 (p<0.0001) scores compared to H. pylori-negative patients. At 12 weeks post-eradication, the mean levodopa onset time shortened by 14 minutes (p = 0.011). The mean ON duration time increased by 56 minutes at week 6 (p = 0.041) and 38 minutes at week 12 (p = 0.035). The total UPDRS scores (p<0.0001), scores for parts II (p = 0.001), III (p<0.0001) and IV (p = 0.009) were significantly better. The total PDQ-39 scores (p = 0.001) and subdomains mobility (p = 0.002), ADL (p = 0.001), emotional well being (p = 0.026) and stigma (p = 0.034) significantly improved. The PD NMSQ did not show significant improvement.

conclusionsH. pylori eradication improved levodopa onset time, ON duration, motor severity and quality of life parameters. Screening and eradication of H. pylori is inexpensive and should be recommended in PD patients, particularly those with erratic response to levodopa.

trial registrationClinicalTrials.gov NCT02112812.

Indexed as

AgedAmoxicillinAnti-Bacterial AgentsAntiparkinson AgentsBreath TestsClarithromycinComorbidityDrug Therapy, CombinationEsomeprazoleFemaleHelicobacter InfectionsHelicobacter pyloriHumansLevodopaMaleMiddle AgedAmoxicillinAnti-Bacterial AgentsAntiparkinson AgentsClarithromycinEsomeprazoleLevodopa

Identifiers

PMID25411976
PMCPMC4239049
OpenAlexW2079589247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.